SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SSgA Active Trust - SPDR S&P 500 ETF Trust

SPY is experiencing significant volatility, prompting discussions about a potential market correction or even the start of a bear market. Fed Governor Lisa Cook's comments regarding high valuations are being cited as a possible catalyst for the downturn. Community sentiment is mixed, with both bulls and bears actively trading the volatility and debating potential bottom levels and future direction.

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

Despite strong earnings, NVIDIA is experiencing a sell-off, leading to widespread discussion about potential market manipulation and whether the AI bubble is bursting. Community sentiment is largely negative, with many questioning the high valuations and pointing to potential downside. Some traders are expressing frustration, while others are seizing the opportunity to buy the dip or profit from short positions.

Invesco Capital Management LLC - Invesco QQQ Trust Series 1

The $QQQ is experiencing significant volatility, driven by an intense intraday sell-off despite initially gapping up on strong earnings from major tech companies. Community sentiment is shifting rapidly, with many traders expressing shock and questioning the market's fundamentals as the index reverses sharply. Discussions revolve around potential manipulation, the influence of macroeconomic factors, and whether this signals a broader market correction or just a short-term pullback.

Bitcoin is the world's first decentralized cryptocurrency, created in 2009 by the pseudonymous Satoshi Nakamoto. It enables peer-to-peer electronic cash transactions without intermediaries like banks or governments, operating on a blockchain secured by Proof of Work mining and the SHA-256 cryptographic algorithm.   With a fixed supply cap of 21 million coins and programmatic halvings every four years that reduce miner rewards, Bitcoin is designed as a deflationary digital asset often called "digital gold." Its value stems from solving the double-spending problem without trusted intermediaries, creating the first truly scarce digital asset with censorship resistance and permissionless access that no government, corporation, or individual can control.  Bitcoin operates as a decentralized peer-to-peer network where transactions are recorded on a public ledger called the blockchain, distributed across thousands of computers globally. Transactions are grouped into blocks added approximately every 10 minutes through mining, where specialized computers compete to solve complex mathematical puzzles.   Bitcoin has achieved mainstream adoption through multiple vectors. The January 2024 SEC approval of 11 spot Bitcoin ETFs opened Bitcoin investment to traditional finance participants, and corporations like Strategy (formerly MicroStrategy) are using Bitcoin as a treasury reserve asset to protect against currency debasement, offering MSTR holders amplified exposure to Bitcoin.   The Bitcoin ecosystem continues to evolve with innovations like Ordinals, which emerged in January 2023 to enable NFT-like functionality directly on Bitcoin, and BRC-20 tokens, an experimental standard for creating fungible tokens using Ordinal inscriptions. BTCFi (Bitcoin Finance) represents emerging financial applications extending beyond Bitcoin's traditional role, with protocols like Babylon allowing Bitcoin holders to stake BTC to secure Proof of Stake chains.

Bitcoin

Bitcoin is trending downwards, sparking debate about potential support levels and whether this signals the end of the current cycle. Community members are discussing Michael Saylor's position and potential liquidations, while others point to broader market factors and potential manipulation. The conversation includes opinions on Bitcoin's role as a store of value and its impact on the wider market.

Advanced Micro Devices, Inc. engages in the provision of semiconductor businesses. It operates through the following segments: Data Center, Client, Gaming, and Embedded. The Data Center segment includes server-class CPUs, GPUs, AI accelerators, DPUs, FPGAs, SmartNICs, and Adaptive SoC products. The Client segment refers to the computing platforms, which are a collection of technologies that are designed to work together to provide a more complete computing solution. The Gaming segment is a fundamental component across many products and can be found in APU, GPU, SoC or a combination of a discrete GPU with another product working in tandem. The Embedded segment focuses on the embedded CPUs, GPUs, APUs, FPGAs, and Adaptive SoC products. The company was founded by W. J. Sanders III on May 1, 1969 and is headquartered in Santa Clara, CA.

Advanced Micro Devices Inc.

Advanced Micro Devices Inc

AMD is trending amid a broader tech sector pullback and ahead of Nvidia's earnings report, with some traders expressing concerns about an AI bubble. The community is debating whether the dip presents a buying opportunity or if further declines are expected, while others are highlighting AMD's partnerships and potential for growth in the AI space. Discussions also include potential price targets and the impact of macroeconomic factors on the stock's performance.

Strategy, Inc. engages in the provision of enterprise analytics and mobility software. The firm designs, develops, markets, and sells software platforms through licensing arrangements and cloud-based subscriptions and related services. Its product packages include Hyper. The company was founded by Michael J. Saylor and Sanjeev K. Bansal on November 17, 1989, and is headquartered in Vienna, VA.

Strategy Inc. - Ordinary Shares - Class A

Strategy

Strategy is trending downwards as it amplifies Bitcoin's movements, with concerns rising about debt leverage and potential liquidation. Community discussions revolve around whether the stock is overvalued and how much further it could drop, with some anticipating a significant decline. Broader market commentary suggests potential risks tied to hedge fund activity and overall market valuations which may impact Strategy.

Safe & Green Holdings Corp. is a design and construction services company, which engages in the provision of code engineered cargo shipping containers. It operates through the following segments: Construction, Medical, Development, and Corporate and Support. The Construction Services segment includes the manufacturing of unit SG ECHO and other modules projects. The Medical segment consists of joint venture COVID-19 laboratory operations. The Development segment focuses on real property development. The Corporate and Support segment includes general corporate expenses such as the executive office, corporate finance, accounting, audit, tax, human resources, risk management, information technology, marketing, and legal groups, corporate overhead, and other items not allocated to any of the company's other segments. The company was founded on December 29, 1993 and is headquartered in Miami, FL.

Safe & Green Holdings Corp

Safe & Green Holdings Corp is trending due to a shift in business strategy and community speculation around a potential short squeeze. Traders are actively debating float size, short interest, and the possibility of a GME-like scenario, while others express concerns about pump-and-dump schemes and dilution. High volatility and trading volume contribute to the ongoing discussion.

Ripple is the catchall name for the cryptocurrency platform, the transactional protocol for which is actually XRP, in the same fashion as Ethereum is the name for the platform that facilitates trades in Ether. Like other cryptocurrencies, Ripple is built atop the idea of a distributed ledger network which requires various parties to participate in validating transactions, rather than any singular centralized authority. That facilitates transactions all over the world, and transfer fees are far cheaper than the likes of bitcoin. Unlike other cryptocurrencies, XRP transfers are effectively immediate, requiring no typical confirmation time.  Ripple was originally founded by a single company, Ripple Labs, and continues to be backed by it, rather than the larger network of developers that continue bitcoin’s development. It also doesn’t have a fluctuating amount of its currency in existence. Where bitcoin has a continually growing pool with an eventual maximum, and Ethereum theoretically has no limit, Ripple was created with all of its 100 billion XRP tokens right out of the gate. That number is maintained with no mining and most of the tokens are owned and held by Ripple Labs itself — around 60 billion at the latest count.  Even at the recently reduced value of around half a dollar per XRP, that means Ripple Labs is currently sitting on around $20 billion worth of the cryptocurrency (note: Ripple’s price crashed hard recently, and may be worth far less than $60 billion by time you read this). It holds 55 billion XRP in an escrow account, which allows it to sell up to a billion per month if it so chooses in order to fund new projects and acquisitions. Selling such an amount would likely have a drastic effect on the cryptocurrency’s value, and isn’t something Ripple Labs plans to do anytime soon.  In actuality, Ripple Labs is looking to leverage the technology behind XRP to allow for faster banking transactions around the world. While Bitcoin and other cryptocurrencies are built on the idea of separating financial transactions from the financial organizations of traditional currencies, Ripple is almost the opposite in every sense.  XRP by Ripple price can be found on this page alongside the market capitalization and additional stats.

Ripple

XRP is trending as the community debates its future amidst market volatility and the launch of new ETFs; traders are actively discussing potential price floors and whether upcoming events will act as catalysts. Community members are split on whether to buy the dip or brace for further declines, while some question XRP's utility and its correlation with Bitcoin's price movements.

Micron Technology, Inc. engages in the provision of innovative memory and storage solutions. It operates through the following segments: Compute and Networking Business Unit (CNBU), Mobile Business Unit (MBU), Embedded Business Unit (EBU), and Storage Business Unit (SBU). The CNBU segment includes memory products and solutions sold into client, cloud server, enterprise, graphics, and networking markets. The MBU segment is involved in memory and storage products sold into smartphone and other mobile-device markets. The EBU segment focuses on memory and storage products sold into automotive, industrial, and consumer Markets. The SBU segment consists of SSDs and component-level solutions sold into enterprise and cloud, client, and consumer storage markets. The company was founded by Ward D. Parkinson, Joseph Leon Parkinson, Dennis Wilson, and Doug Pitman on October 5, 1978 and is headquartered in Boise, ID.

Micron Technology Inc.

Micron Technology Inc

Micron is trending as traders digest a recent price target increase from UBS, countered by potential concerns over capex spending. Community discussion revolves around the sustainability of the rally and whether the stock is currently overbought, especially in light of the broader AI-driven memory demand narrative. Some traders are pointing to potential short-term pullback scenarios.

Rocket Lab Corp. engages in the development of rocket launch and control systems for the space and defense industries. It operates through the Launch Services and Space Systems segments. The Launch Services segment provides launch services to customers on a dedicated mission or ride share basis. The Space Systems segment consists of spacecraft engineering and design services, spacecraft components, spacecraft manufacturing, and on-orbit mission operations. The company is headquartered in Long Beach, CA.

Rocket Lab Corp.

Rocket Lab USA Inc

Rocket Lab is trending downwards, with community members citing general market conditions and a delayed Neutron launch as catalysts for the dip, despite a recent successful launch and positive earnings report. The community is debating whether to buy the dip or brace for further declines, with some expressing frustration while others remain bullish on the company's long-term potential and are taking the opportunity to add to their positions. Some traders attribute the drop to short sellers and broader market trends.

statis crypto Watchlist

Ethereum

Solana

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

VNDA Stock Jumps on Upbeat Tradipitant Data Cutting GLP-1 Side Effects

Vanda Pharmaceuticals stock rallies after phase II data show tradipitant sharply cuts Wegovy-related nausea and vomiting in overweight and obese adults.

Vanda Pharmaceuticals Surges 21% After Positive Tradipitant Trial In GLP-1 Adjunct Setting

(RTTNews) - Vanda Pharmaceuticals Inc. (VNDA) jumped 21.02% to $5.32, up $0.92, after announcing positive topline results from its phase III study of tradipitant in preventing nausea and vomiting...

Side Effects From Wegovy? This Vanda Pharmaceuticals' Drug Halves Vomiting In Patients

Vanda Pharmaceuticals' tradipitant successfully reduced Wegovy-induced vomiting by 50% in a clinical trial. Phase 3 anticipated in H1 2026.read more...

Vanda Pharmaceuticals Reports Positive Results for Tradipitant in Preventing GLP-1 Induced Nausea and Vomiting

Vanda Pharmaceuticals Reports Positive Results for Tradipitant in Preventing GLP-1 Induced Nausea and Vomiting Vanda Pharmaceuticals Reports Positive Results for Tradipitant in Preventing GLP-1...

Acadian Asset Management LLC Sells 155,159 Shares of Vanda Pharmaceuticals Inc. $VNDA

Acadian Asset Management LLC lessened its holdings in shares of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA - Free Report) by 8.2% during the second quarter, according to the company in its most recent...

Vanda Pharmaceuticals (VNDA) Reports Q3 Loss, Misses Revenue Estimates

Vanda (VNDA) delivered earnings and revenue surprises of -22.58% and -6.24%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Vanda Pharmaceuticals Reports Third Quarter 2025 Financial Results

Vanda Pharmaceuticals Reports Third Quarter 2025 Financial Results Vanda Pharmaceuticals Reports Third Quarter 2025 Financial Results PR Newswire WASHINGTON, Oct. 29, 2025 Fanapt Q3 2025 net product...

Vanda Pharmaceuticals to Announce Third Quarter 2025 Financial Results on October 29, 2025

Vanda Pharmaceuticals to Announce Third Quarter 2025 Financial Results on October 29, 2025 Vanda Pharmaceuticals to Announce Third Quarter 2025 Financial Results on October 29, 2025 PR Newswire...

Retail chatter picked up around Vanda Pharmaceuticals on Thursday after the company formally asked U.S. Food and Drug Administration (FDA) Commissioner Martin Makary to review a decision upholding the approval of two generic versions of its sleep drug Hetlioz, intensifying its fight with regulators just days after winning a separate court battle.In a filing, Vanda said it wants Makary to examine the ruling issued in July by Jacqueline Corrigan-Curay, the outgoing director of the FDA’s Center for Drug Evaluation and Research (CDER).&nbsp;Her decision, made shortly before her retirement, sided with the Office of Generic Drugs in clearing two competing versions of Hetlioz despite what Vanda argues were “significant flaws” in the underlying studies.The company said regulators accepted bioequivalence studies conducted only in Indian male subjects and overlooked data inconsistencies, including one generic that showed blood exposure levels more than twice those seen with Hetlioz.&nbsp;Vanda also criticized what it described as an entrenched FDA bias toward approving generics “regardless of whether they meet the requisite legal and evidentiary standards.”The latest push comes just days after&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/novo-nordisk-cuts-ozempic-cost-to-499-dollars-per-month-for-self-paying-patients/chsOfKDRdXE">Vanda scored a legal win in Washington</a>, where a federal appeals court threw out the FDA’s rejection of Hetlioz as a jet lag treatment.&nbsp;The judges faulted the agency for giving the application only a cursory review and sent it back, saying the FDA must now either approve the drug for that use or give Vanda a proper hearing.&nbsp;The ruling revived a regulatory dispute dating back to 2018, when Vanda first sought approval for the indication.Hetlioz is already cleared in the U.S. to treat Non-24-Hour Sleep-Wake Disorder and sleep problems linked to Smith-Magenis Syndrome. It remains one of Vanda’s key products, generating $16.2 million in the second quarter of 2025, about 31% of the company’s revenue.Vanda said bureaucrats have indicated it may take up to two months for the FDA’s Office of the Commissioner to decide whether Makary himself will review the generics decision.&nbsp;“It is time that the rule of law return to the FDA under Dr. Makary’s leadership,” the company said in its statement.On Stocktwits, retail sentiment for Vanda was ‘bullish’ amid ‘high’ message volume.<a href="https://stocktwits.com/symbol/VNDA">Vanda’s stock</a> has declined nearly 6% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

On Stocktwits, retail sentiment for Vanda (VNDA) was ‘bullish’ amid ‘high’ message volume. (Photo credit: Getty Images)

Retail Buzz Builds As Vanda Urges FDA Chief To Revisit Hetlioz Generics Decision — Alleges “Bias Toward Approvals”

The company argues that regulators relied on narrow study populations and overlooked major data inconsistencies, raising concerns about patient safety.

Equity

Vanda Pharmaceuticals Inc. (VNDA) shares surged 9% on Monday after the company said that a Federal Appeals Court overturned the U.S. Food and Drug Administration’s order denying approval to its drug Hetlioz in the treatment of jet lag disorder.Vanda had submitted its application to the FDA seeking approval for Hetlioz to treat jet lag disorder in October 2018. A federal district court ordered the FDA to resolve the application or commence a hearing with respect to the application after the agency delayed it. However, instead of holding a hearing, the agency issued an order refusing to approve the application, and Vanda subsequently filed a petition for review with the U.S. Court of Appeals for the D.C. Circuit.The appeals court set aside the FDA’s action and stated that the agency’s "treatment of Vanda's evidence is cursory," the company <a target="_blank" rel="noopener noreferrer nofollow" href="https://vandapharmaceuticalsinc.gcs-web.com/node/16556/pdf">said</a> on Monday. The court has remanded the case back to the FDA, where Vanda expects the FDA will either approve the drug application or the company will receive a hearing.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/VNDA">Vanda</a> jumped from ‘bearish’ to ‘bullish’ over the past 24 hours, while message volume stayed at ‘low’ levels.&nbsp;<figure class="image"><img style="aspect-ratio:578/63;" src="https://news.stocktwits-cdn.com/Screenshot_2025_08_18_at_11_58_28_AM_png_ad9d75a67b.webp" alt="VNDA's Sentiment Meter and Message Volume as of 11:55 a.m. ET on Aug. 18, 2025 | Source: Stocktwits" width="578" height="63"><figcaption>VNDA's Sentiment Meter and Message Volume as of 11:55 a.m. ET on Aug. 18, 2025 | Source: Stocktwits</figcaption></figure>A bullish Stocktwits user expects the stock to hit over $5.<stembedurl>https://stocktwits.com/HorizonBull/message/625611441</stembedurl>Another opined that the legal turnaround is a “strongly bullish development” for Vanda.<stembedurl>https://stocktwits.com/BigSqueezeComing/message/625585269</stembedurl>Hetlioz is a prescription medicine approved to treat people with Non-24-Hour Sleep-Wake Disorder and to treat nighttime sleep disturbances in Smith-Magenis Syndrome (SMS).In the second quarter of 2025, Hetlioz's net sales were $16.2 million, accounting for nearly 31% of Vanda’s overall total revenues. VNDA stock is down by about 11% over the past 12 months.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/elon-musk-space-starlink-changes-to-south-africa-black-ownership-rules/chsOhmVRdXO">SpaceX Calls For Changes To South Africa’s Black Ownership Rules For Telecom Companies: Report</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Global stock market chart and trading board - stock photo

Vanda Pharma Stock Rockets 9% After Federal Appeals Court Sets Aside FDA Action: Retail Expects Stock To Cross $5-Mark 

The court has remanded the case back to the FDA, where Vanda expects the agency will either approve the drug application or the company will receive a hearing.

Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. The firm intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder. Its product portfolio includes HETLIOZ, Fanapt, Tradipitant, Trichostatin, and AQW051. The company was founded by Mihael Hristos Polymeropoulos and Argeris N. Karabelas in 2002 and is headquartered in Washington, DC.

VNDA
Vanda Pharmaceuticals Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest VNDA News

VNDAVanda Pharmaceuticals Inc